Suppr超能文献

肠道菌群代谢产物在糖尿病肾病中的致病作用。

The pathogenic role of intestinal flora metabolites in diabetic nephropathy.

作者信息

Tian En, Wang Feng, Zhao Lei, Sun Yan, Yang Jurong

机构信息

The Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Beibei Traditional Chinese Medicine Hospital, Chongqing, China.

出版信息

Front Physiol. 2023 Jul 4;14:1231621. doi: 10.3389/fphys.2023.1231621. eCollection 2023.

Abstract

With the increasing incidence of diabetes, diabetic kidney disease has become a major cause of chronic kidney disease. The role of the gut microbiota in diabetes and its related complications have been extensively investigated; the modulatory effect of the gut microbiota on the host depends on several gut microbial metabolites, particularly short-chain fatty acids, secondary bile acids, and trimethylamine N-oxide. In this review, we focused on the evidence related to the pathogenic role of each of the gut microbial metabolites in diabetic nephropathy. The main novel therapies targeting the gut microbiota include probiotics, dietary prebiotics, synbiotic supplements, and faecal microbiota transplants, although there is no standard treatment principle. Further research is therefore needed to elucidate the link between gut microbes and diabetic nephropathy, and more therapeutic targets should be explored to treat diabetic nephropathy with dysbiosis of the gut microbes.

摘要

随着糖尿病发病率的不断上升,糖尿病肾病已成为慢性肾脏病的主要病因。肠道微生物群在糖尿病及其相关并发症中的作用已得到广泛研究;肠道微生物群对宿主的调节作用取决于几种肠道微生物代谢产物,特别是短链脂肪酸、次级胆汁酸和氧化三甲胺。在这篇综述中,我们重点关注了每种肠道微生物代谢产物在糖尿病肾病中的致病作用相关证据。尽管尚无标准治疗原则,但针对肠道微生物群的主要新型疗法包括益生菌、膳食益生元、合生元补充剂和粪便微生物群移植。因此,需要进一步研究以阐明肠道微生物与糖尿病肾病之间的联系,并且应探索更多治疗靶点来治疗肠道微生物群失调的糖尿病肾病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db39/10352811/b5ede442b3bd/fphys-14-1231621-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验